Given that CYP3A5 activity may exacerbate high blood pressure (HBP) in both fast metabolizing *1/*1 and slow metabolizing (or conditional) *1/*3 and *3/*3 genotypes, and this pathological activity can be modulated with ASO in vitro, developing CYP3A5-directed therapeutics targeting renal disorders is worth consideration. Here, CYP3A5 is linked to kidney disorder.